Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine
Swiss regulatory authorities, including the Swiss Agency for Therapeutic Products [...]
Emergex Appoints Dr. Anthony Sedgwick as Non-Executive Director
Abingdon, Oxon, UK, 17 June 2021 – Emergex Vaccines Holding [...]
Emergex Strengthens Senior Management Team
Appointments of Mr Robin Cohen as Business Development Director and [...]
Emergex Notes U.S. Government Reports Highlighting the Importance of T-Cell Immunity in Controlling Viral Infections
Emergex Notes U.S. Government Reports Highlighting the Importance of T-Cell [...]
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
Bio-Manguinhos, is a world leader in vaccine development and [...]
Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases
Investor support further endorsement of vaccine development strategy Novel approach [...]
Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells
First detailed, empirical analysis of Class 1 epitopes presented by [...]
Emergex Vaccines forms US subsidiary (Emergex USA) by acquisition of laboratories, technology and assets of US-based T cell specialist biotech ImmProNano
Acquisition brings critical technical pre-clinical vaccine development capabilities in-house and [...]
Emergex and Bio-Manguinhos/Fiocruz Elucidate T Cell Epitopes Produced by Commercial Yellow Fever Vaccine
First identification of epitopes which shape CD8 T cell response [...]
Emergex Signs Agreement with George Mason University for Highly Pathogenic RNA Virus Studies
Emergex Vaccines and George Mason University’s (Mason) National Center for [...]